No va r t i s  In s t i tu te s  fo r  B ioMed i ca l  Re sea r ch
QVM149
CQVM149B2203
A  random ized ,  doub le -b l ind ,  p lacebo - con t ro l led ,  
th ree - pe r iod  c ross- ove r  s tudy to  assess  the  
pha rmacodynam ics ,  sa fe ty,  to le rab i l i ty ,  and  
pha rmacok ine t ics  o f  two  o ra l ly inha led  indaca te ro l  sa l t s
(ma lea te  and  ace ta te )  de l iv e red  via  the  Concep t1  inha la t ion  
dev ice  in  pa t ien ts  wi th  as thma
S ta t is t ica l  Ana lys is  P lan  (SAP )
Documen t  t ype : SAP  Do cumen ta t ion  –N IBR  
Do cumen t  s ta tu s : F ina l2 .0  Amendmen t  1
Re lease  da te : 16- Ap r- 2018
Numbe r  o f  pages : 17Pe r sona l  Da ta
P rope r ty  o f  Nova r t is
Fo r  bus iness  use  on ly
May  no t  be  used ,  d ivu lged ,  pub l ished  o r  o the rw ise  d isc losed
w i thou t  the  consen t  o f  Nova r t is
No va r t i s Fo r  bus iness  use  on ly Page  2
SAPAmendmen t  1 CQVM149B2203
Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Fo r  bus iness  use  on ly Page  3
SAPAmendmen t  1 CQVM149B2203
Tab le  o f  con ten ts
T a b l e  o f  c o n t e n t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
L i s t  o f  t a b l e s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
1 I n t r o d u c t i o n. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
1 . 1 S c o p e  o f  d o c um e n t. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
1 . 2 S tudy r e f e r en c e  do cum en t a t ion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
1 . 3 S tudy o b j e c t i v e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
1 . 3 . 1 P r im a ry o b j e c t i v e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
1 . 3 . 2 S e cond a ry o b j e c t i v e ( s ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
1 . 4 S tudy d e s ign  and  t r e a tm en t . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
2 F i r s t  i n t e r p r e t a b l e  r e s u l t s  (F IR ). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
4 S t a t i s t i c a l  m e t h o d s :  A n a l y s i s  s e t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
5 S t a t i s t i c a l  m e t h o d s  f o r  P h a rm a c o k i n e t i c  (PK )  p a r am e t e r s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .9
5 . 1 V a r i a b l e s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
5 . 2 D e s c r i p t i v e  a n a ly se s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
5 . 3 S t a t i s t i c a l  m o d e l ,  a s s um p t i o n s  a n d  h yp o t h e s e s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
5 . 3 . 1 M o d e l  c h e c k i n g  p r o c e d u r e s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
5 . 3 . 2 G r a p h i c a l  p r e s e n t a t i o n  o f  r e s u l t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 0
6 S t a t i s t i c a l  m e t h o d s  f o r  P h a rm a c o dy nam i c  (PD )  p a r am e t e r s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 0
6 . 1  Pr im a ry  ob j e c t iv e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 0
6 . 1 . 1 V a r i a b l e s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 0
6 . 1 . 2 D e s c r i p t i v e  a n a ly se s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 0
6 . 1 . 3 S t a t i s t i c a l  m o d e l ,  a s s um p t i o n s  a n d  h yp o t h e s e s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 0
6 . 2 S e cond a ry ob j e c t iv e s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 2
6 . 2 . 1 V a r i a b l e s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 2
6 . 2 . 2 D e s c r i p t i v e  a n a ly se s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 3
6 . 2 . 3 S t a t i s t i c a l  m o d e l ,  a s s um p t i o n s  a n d  h yp o t h e s e s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 3
6 . 3 Exp lo r a to ry o b j e c t i v e s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 4
6 . 3 . 1 V a r i a b l e s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 4
6 . 3 . 2 D e s c r i p t i v e  a n a ly se s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 4
7 S t a t i s t i c a l  m e t h o d s  f o r  s a f e t y and  to l e r ab i l i ty  d a t a . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 4
7 . 1 V a r i a b l e s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 4
7 . 2 D e s c r i p t i v e  a n a ly se s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 5
7 . 3 G r a p h i c a l  p r e s e n t a t i o n. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .C
 
 
1 7Co rpo ra te  Con f iden t ia l  In fo rma t ion
Co rpo ra te  Con f iden t ia l  In fo rma t ionCo rpo ra te  Con f iden t ia l  In fo rma t ion
Novartis For business use only Page 4
SAP Amendm ent 1 CQVM149B2203
List of tables
Table 4-1 Protocol deviation codes and anal ysis sets .............................................. 8
Novartis For business use only Page 5
SAP Amendm ent 1 CQVM149B2203
1 Introduction 
1.1 Scope of document
The RAP documents contain detailed informat ion to aid the production of Statistics & 
Programming input into the Clinical Study  Report (CSR) for trial “CQV M149B2203 ”.
The Statistical analysis plan (SAP) 
describes the implementation of the statistical analysis 
planned in the protocol.
1.2 Stud y reference documentation
Final study  protocol is finalized at the time of the finalization of Statistical Analy sis Plan .
This SAP Amendment 1 is based on the final version of the
Study  protocol, v00, 28 Feb 2017
No va r t i s Fo r  bus iness  use  on ly Page  6
SAPAmendmen t  1 CQVM149B2203
1 .3 S tudy  ob jec t ives
1 .3 .1 P r ima ry ob jec t ives
T o  a s s e s s  t h e  b r o n c h o d i l a t o r  e f f e c t  o f  o r a l ly  i n h a l e d  i n d a c a t e r o l  s a l t s  (m a l e a t e  a n d  a c e t a t e )  
i n  s u b j e c t s  w i t h  a s t hm a  c om p a r e d  t o  p l a c e b o  a s  m e a s u r e d  b y  t r o u g h  FEV 1  a f t e r  14  d ay s  o f  
t r e a tm e n t
1 .3 .2 Seconda ry ob jec t ive (s )
T o  a s s e s s  t h e  s t e a dy  s t a t e  p h a rm a c o k i n e t i c s  o f  ind a c a t e ro l  a f t e r  14  d ay s  o f  t r e a tm e n t  o f  
o r a l ly  i n h a l e d  i n d a c a t e r o l  s a l t s  (m a l e a t e  a n d  a c e t a t e )  i n  s u b j e c t s  w i t h  a s t hm a .
T o  a s s e s s  t h e  b r o n c h o d i l a t o r  e f f e c t  o f  o r a l ly  i n h a l e d  i n d a c a t e r o l  s a l t s  (m a l e a t e  a n d  a c e t a t e )  
i n  s u b j e c t s  w i t h  a s t hm a  c om p a r e d  t op l a c e b o  a s  m e a s u r e d  by :
T im e  t o  p e a k  FEV 1  o n  D a y 1 4
FEV 1 ,  FEV 1  (%  p r e d i c t e d ) ,  FVC ,  FVC  (%  p r e d i c t e d ) ,  FEV 1 /FVC ,  a n d  FEF 2 5-
7 5%  a t  e a c h  p o s t - do s e  t im e  po in t  a f t e r  14  d ay s  o f  t r e a tm en t
S t a n d a r d i z e d  FEV 1  AUC  f r om  p r e- do s e  to  4  h  po s t - do s e  on  D ay  1 4  o f  t r e a t m e n t
T o  a s s e s s  t h e  b r o n c h o d i l a t o r  e f f e c t  o fi n d a c a t e r o l  a c e t a t e ,  i n d a c a t e r o l  m a l e a t e ,  a n dp l a c e b o  
by  comp a r ing  th e  p r e - m ed i c a t ion(m o r n i n g  ( p r e - d o s e )  a n d  e v e n i n g )  p e a kexp i r a to ry  f l ow  
( PEF )  r a t e  c o l l e c t e d  b e tw e e nd ay s  8  a n d  1 4  o f  e a c h  t r e a tm e n t .
T o  a s s e s s  r e s c u e  m e d i c a t i o n  u s a g e  f o r  i n d a c a t e r o l  s a l t s  (m a l e a t e  a n d  a c e t a t e )  i n  
c om p a r i s o n  t o  p l a c e b o .
T o  a s s e s s  t h e  s a f e ty  a n d  t o l e r a b i l i t y  o f  i n d a c a t e r o l  s a l t s  (m a l e a t e  a n d  a c e t a t e )  i n  
c om p a r i s o n  t o  p l a c e b o  o f  1 4  d a y s  o f  t r e a tm e n t  i n  e a c h  t r e a tm e n t  p e r i o d .
1 .4 S tudy  des ign  and  t rea tmen t
F igu re  1-1 S tudy des ignCo rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Fo r  bus iness  use  on ly Page  7
SAPAmendmen t  1 CQVM149B2203
Th i s  i s  a  con f i rm a to ry ,  r andom i z ed ,  d o u b l e  b l ind ,  p l a c e b o- con t ro l l ed ,  th r e e - p e r iod  comp l e t e
b lo c k ,  c r o s s o v e rs tudy  in  p a t i e n t sw i t h  a s t hm a .
S u b j e c t s  w h o  m e e t  a l l  o f  t h e  e l ig ib i l i ty  c r i t e r i a  w i l l  b e  r a n d om i z e d  to  o n e  o f  s ix  t r e a tm e n t
s e q u e n c e s  a s  d e s c r i b e d  in  F i g u r e  3 - 1 .  Th ey  w i l l  r e c e iv e  th e i r  f i r s t  do s e  on  t h e  m o r n i n g  o fD ay  
1 .  S u b j e c t s  w i l l  b e  d o s e d  b e tw e e n  0 6 : 0 0  a .m .  a n d  1 0 : 0 0  a .m .  u n d e r  t h e  g u i d a n c e  a n dsup e rv i s ion  
o f  t h e  i n v e s t i g a t o r  o r  d e s i g n e e  a f t e r  a n  add i t ion a l  t r a i n i n g  f o r  co r r e c t  u s e  o f  th eC o n c e p t 1  
i n h a l a t i o n  d e v i c e .  D o s i n g  o f  i n v e s t i g a t i o n a l  p rodu c t  a n d  b a c k g r o u n d  IC Sm e d i c a t i o n  s h o u l d  
o c c u r  a t  app rox im a t e ly  t h e  s am e  t im e  o f  t h e  d ay  t h r o u g h o u t  t h e  s tudy .PEFm e a s u r em e n t s  ( i f  
no t  a l r e a d y  p e r fo rm ed  a t  h om e  o n  t h e  m o r n i n g  o f  D ay 1  o r  D ay 1 4 )  shou ldb e  t a k e n  p r i o r  to  
p r e - do s e  sp i rom e t ry  a n d  s a f e t y  a s s e s sm e n t s.
O n  D ay 1 ,  sub j e c t s  w i l l  l e a v et h e  c l i n i c  a f t e r  t h e  c om p l e t i o n  o f  t h e  r e q u i r e d  a s s e s sm e n t s  and
w i l l  do s e  a t  hom e  on c e  d a i ly in  th e  mo rn ing  on  D ay s  2  to  13 .  Du r ing  d ay s  2  - 13 ,  sub j e c t s  w i l l
r e c o r d  d r u g  a dm i n i s t r a t i o n ,  PEF  m e a s u r em e n t s ,  mou th  r i n s i n g ,  a n d  r e s c u e  m e d i c a t i o n  u s e  in
t h e i r  d i a ry .  S u b j e c t s  w i l l  b e  d om i c i l e d  a t  t h e  c l i n i c  o n  t h e  m o r n i n g  o f  D ay 1 4 ,  f o r  d r ug
adm in i s t r a t ion  and  D ay  14  v i s i t  a s s e s sm en t s .Sub j e c t s  w i l l  b e  d i s ch a rg ed  on  D ay 15  fo l low ing  
t h e  f i n a l  PK  a n d  s a f e t y  b l o o d  s am p l e  d r awa n d  c om p l e t i o n  o f  D a y  15  a s s e s sm en t s .
Aw a s h o u t  p e r i o d  o f  7  -14  d ay s  w i l l  s e p a r a t e  e a c h  t r e a tm e n t  p e r i o d .  
E p o c h  Comp l e t ion  a s s e s sm en t s  mu s t  b e  c o n d u c t e d  fo r  s u b j e c t s  who  c om p l e t e  a l l  th r e e
t r e a tm e n t  p e r iod s  o r  a t  any  t im e  a  s u b j e c t  e a r l y  t e rm i n a t e s  f rom  t h e  t r i a l .  .  T h e  l a s t  v i s i t  (D a y
6 5 )  o fT r e a tm e n t  p e r i o d  3  w i l l  a l s o  b e  t h e  e n d  o f  s t u d y  v i s i t .  S u b j e c t ss h o u l d  b e  d i s c h a r g e d  f rom  
t h e  s i t e  a f t e r  t h e  c om p l e t i o n  o f  D a y  1 5  a s s e s sm e n t s  f o r  a l l  3p e r i o d s .
2 F i rs t  in te rp re tab le  resu l ts  (F IR )
F i r s t  i n t e r p r e t a b l e  r e s u l t s  (F IR )  w i l lb e  p rov id ed  fo r  th i st r i a l .
4 S ta t is t ica l  me thods :  Ana lysis  se tsCo rpo ra te  Con f iden t ia l  In fo rma t ion
F o r  a l l  a n a l ys i s  s e t s ,  s u b j e c t s  w i l l  b e  a n a l y ze d  a c c o r d i n g  t o  t h e  s t u d y  t r e a tm e n t ( s )  r e c e i v e d .  Co rpo ra te  Con f iden t ia l  In fo rma t ion
Novartis For business use only Page 8
SAP Amendm ent 1 CQVM149B2203
The safet y analysis set will include all subjects that received an y stud y drug .
The PK analy sis set will include all subjects with at least one available valid (i.e. not flagged 
for exclusion) PK concentration measurement, who received any study  drug and experienced 
no major protocol deviations with relevant impact on PK data .
The PD analysis set will include all subjects with any available PD data, who received any study 
drug and experienced no protocol deviations with relevant 
impact on PD data.
The PD anal ysis set will include all subjects with available PD parameter data who received
any study  drug and experienced no major protocol deviations with relevant impact on PD data . 
Any PD data for the primary  endpoint obtained within 6 hours after rescue medication use or
within 7 days of s ystemic corticosteroid will be set to missing.
The anal ysis sets and protocol deviation codes are related as follows:
Table 4-1 Protocol deviation codes and analy sis sets
Category
Deviation codeText description of deviation Data exclusion
Subjects are excluded from Safety analysis in case of these 
PDs: Exclude subject from Safety
analysis set 
INCL01 Deviation from inclusion criteria: In the 
unlikely  event that a subject was included 
without w ritten informed consent , then 
their data will not be usedYes
Subjects are excluded from PD analysis in case of these PDs: Exclude subject from PD 
analysis set
INCL 01 Deviation from inclusion criteria: In the 
unlikely  event that a subject was included 
without w ritten informed consent , then 
their data will not be usedYes
Subjects are excluded from PK analysis in case of these PDs: Exclude subject from PK 
analysis sets
INCL 01 Deviation from inclusion criteria: In the 
unlikely  event that a subject was included 
without w ritten informed consent , then 
their data will not be usedYes
If updates to this table are needed, an amendment to the SAP needs to be implemented prior to
DBL .
No va r t i s Fo r  bus iness  use  on ly Page  9
SAPAmendmen t  1 CQVM149B2203
5 S ta t is t ica l  me thods  fo r  Pha rmacok ine t ic  (PK )  pa rame te rs
5 .1 Va r iab les  
T h e  c o n c e n t r a t i o n s  o f  i n d a c a t e r o l  i n  p l a sm a  w i l l  b e  d e t e rm i n e d  by  a  v a l id a t ed  L C -MS /MS
m e t h o d ;
O t h e r  p h a rm a c o k i n e t i c  p a r am e t e r s  m a y b e  d e t e rm i n e d  a s  a p p r o p r i a t e .  
5 .2 Desc r ip t ive  ana lyses
I n d a c a t e r o l  p l a sm a  con c en t r a t ion s  w i l l  b e  l i s t ed  by  t r e a tm e n t  s equ en c e ,  sub j e c t ,  p r o f i l e  d ay , and  
s am p l i n g  t im e  p o i n t .  D e s c r ip t iv e  summ a ry  s t a t i s t i c s  w i l l  b e  p r o v i d e d  b y  t r e a tm e n t ,  p r o f i l ed ay ,  
a n d  s am p l i n g  t im e  p o i n t .  Summ a ry s t a t i s t i c s  w i l l  i n c l u d e  m e a n  ( a r i t hm e t i c  a n dg e om e t r i c ) ,  SD ,  
CV  ( a r i t hm e t i c  a n d  g e om e t r i c ) ,  m e d i a n ,  m i n im um  a n d  m a x im um .
C o n c e n t r a t i o n s  b e low  LLOQ  wi l l  b e  t r e a t e d  a s  z e ro  in  summ a ry  s t a t i s t i c s .  A  g e om e t r i c  m e an
w i l l  n o t  b e  r e p o r t e d  i f  t h e  d a t a s e t  i n c l u d e s  z e r o  v a l u e s .
P h a rm a c o k i n e t i c  p a r am e t e r s  w i l l  b e  l i s t ed  by  t r e a tm e n t  s e q u e n c e ,  p ro f i l e  d ay ,  a n d  sub j e c t .  
D e s c r i p t i v e  summ a rys t a t i s t i c s  w i l l  b e  p r o v id ed  by  t r e a tm e n t  and  p ro f i l e  d ay .  S umm a r y  
s t a t i s t i c s  w i l l  i n c l u d e  m e a n( a r i t hm e t i c  a n d  g e om e t r i c ) ,  SD ,  and  CV  ( a r i t hm e t i c  a n d  g eom e t r i c ) ,  
m e d i a n ,  m i n im um  a n dm a x im um .  A n  e x c e p t i o n  t o  th i s  i s  Tm a x  w h e r e  m e d i a n ,  m i n im um  a n d  
m ax imum  w i l l  b ep r e s e n t e d .
5 .3 S ta t is tica l  mode l ,  assump t ions  and  hypo theses
T h e  l o g  t r a n s f o rm e d  p h a rm a c o k i n e t i c  p a r am e t e r s  AUC 0- 2 4 h , s s a n d  Cm a x , s s o n  d a y  1 4  w i l lb e  
c om p a r e d  f o r  i n d a c a t e r o l  a c e t a t e  ( t e s t )  r e l a t i v e  to  ind a c a t e ro l  m a l e a t e  ( r e f e r e n c e )  u s i n g  am ix ed  
e f f e c t s  m o d e l  w i th  s e q u e n c e ,  t r e a tm e n t  a n d  p e r iod  a s  f ix ed  e f f e c t s  a n d  sub j e c t  n e s t e dw i th in  
s e q u e n c e  a s  r andom  e f f e c t .  Body  w e igh t  a s s e s s ed  in  p e r iod  1  w i l l  b ei n c l u d e d  a s  acon t inuou s  
c o v a r i a t e  and  app l i ed  a s  a  f ix ed  e f f e c t  in  th e  mod e l .  Th e  e s t im a t e s  o f  th e  t r e a tm en t  d i f f e r en c e s
( i n d a c a t e r o l  a c e t a t e  ( t e s t )  v s .  m a l e a t e  ( r e f e r e n c e ) ;  F r e l )  a l o n g  w i th  t h e i r  9 0%  c o n f i d e n c e
i n t e r v a l s  w i l l  b e  ob t a in ed .  T h e  e s t im a t e s  a n d  c o n f i d e n c e  in t e rv a l s  w i l l  b e  t r a n s f o rm e d  b a ck  to
t h e  o r i g i n a l  s c a l e  to  p rov id e  r a t i o s  o f  t h e  g e om e t r i c  m e a n s  t o g e t h e r  w i tht h e i r  c o r r e s p o n d i n g
9 0%  c o n f i d e n c e  i n t e r v a l s .
Tm ax , s s  w i l l  b e  an a ly z ed  u s i n g  n o n - p a r am e t r i c  m e t h o d s .  T h e  m e d i a n  d i f f e r e n c e  a n d  th e90%  
c o n f i d e n c e  in t e rv a l  o f  t h e  m ed i an  d i f f e r e n c e  in  Tm ax , s s  w i l l  b e  e s t im a t e d  u s ing  Hodg e s-
L e hm a n n  e s t im a t i o n  p r o c e d u r e .
5 .3 .1 Mode l  check ing  p rocedu resCo rpo ra te  Con f iden t ia l  In fo rma t ion
A l l  d r u g  c o n c e n t r a t i o n s  b e l ow  t h e  low e r  l im i t  o f  q u a n t i f i c a t i o n  (LLOQ )  w i l l  b e  r e p o r t e d  a s  
“ z e r o ”  a n d  w i l l  b e  t r e a t e d  a s  z e r o  f o r  c a l c u l a t i o n  o f  PK  p a r am e t e r s .Co rpo ra te  Con f iden t ia l  In fo rma t ion
Novartis For business use only Page 10
SAP Amendm ent 1 CQVM149B2203
Subjects with missing PK parameters (e.g. Cmax,ss, and AUC0 -24h,ss) in some but not all 
periods will be included in a mixed model analy sis.
5.3.2 Graphical p resentation of results
Individual concentration -time profiles and mean profiles with SD bars will be presented for Day 
14 PK data.
6 Statistical methods for Pharmacody namic (PD) parameters
6.1 Primary  objective
The primary  objective is to assess the bronchodilator effect of orally inhaled indacaterol salts 
(maleate and acetate) in subjects with asthma compared with placebo as measured by trough 
FEV1 after 14 day s of treatment .
6.1.1 Variab les 
The primary variable is trough FEV1 after 14 da ys of treatment. Trough FEV1 is defined as the 
average of the FEV1 measurements at 23 h 15 min and 23 h 45 min post dose.
6.1.2 Descriptive analy ses
Trough FEV1 will be listed by treatment sequence, subject and visit/time and descriptive
summary  statistics will be provided by treatment and visit/time. Summary  statistics willinclude 
arithmetic mean, SD, CV (arithmetic), median, minimum and maximum.
6.1.3 Statistical model, assumptions and hy potheses
The following hypothesis will be tested for each of indacaterol salts (acetate and maleate) versus 
placebo separately :
H0(Null Hy pothesis) : There is no difference in terms of the trough FEV1 after 14 day s of 
treatment between:
                                      Indacaterol acetate and placebo                   
                                                          
OR
                                    Indacaterol maleate andplacebo
H1(Alternative Hy pothesis) : There is a difference in terms of the trough FEV1 after 14 day s 
of treatment between:                         
                                     Indacaterol acetate and placebo                   
                                                  AND
                               Indacaterol maleate andplacebo
No adjustments will be made for multiplicity  because the objective is to prove that both
formulations must be statistically  significantl y different from placebo each at 2-sided 5% level
of significance.
Novartis For business use only Page 11
SAP Amendm ent 1 CQVM149B2203
The trough FEV1 after 14 days of treatment will be analyzed using an analy sis of variance 
(ANOVA) with treatment, period and sequence as fixed effects and subject nested within 
sequence will be included as a random effect. The Kenward -Roger approximation w ill be used 
to estimate denominator degrees of freedom. 
The final model estimates will include the LS mean for each treatment (indacaterol acetate, 
maleate and placebo) together with standard error (SE), the adjusted mean difference between 
indacaterol salts (acetate and maleate) and placebo, and corresponding two-sided 95% 
confidence intervals and P
-value for the differences (acetate vs placebo and maleate vs placebo) 
using placebo as reference treatment. 
Additionally  as a secondary  consideration, an estimate of the differences in trough FEV1 
between indacaterol acetate (test) and indacaterol maleate (reference) will be calculated 
together with the corresponding two sided 95% confidence intervals.
6.1.3.1 Model checking procedures
Subjects withdrawn for any reaso ns other than safety  and tolerability  may be replaced on a case 
by case basis.
If one of the 23h 15 min and 23h 45 min values are missing (or set to missing) then the
remaining non -missing value will be taken as trough FEV1. If both values are missing, or ifthe 
subject withdrew from the study , regardless of the reason for discontinuation, then trough FEV1 
will be regarded as missing.
If any of the values used in the trough FEV1 are collected within six hours of rescue medication 
or 7 days of systemic corticosteroid then the individual FEV1 within 6 hours after rescue 
medication use or within 7 days of systemic corticosteroid will be set to missing .If rescue 
medication is taken during the 24 hour spirometry assessments then from the time of the rescue 
medi cation intake, all post- time point   spirometry  assessments will be considered as missing in 
this treatment period.
Subgroup analysis:
The primary  analysis will be performed by subgroup of patients based on their compliance of 
study  medication within the 7 days before the spirometry assessment: if spirometry assessment 
is done during day 14, then compliance will be calculated between day  8 and day  14 on a total 
number of 7 doses.
This analysis will be provided per compliance of study  medication within the 7 days before
spirometry  assessment defined as follows:
<80% Compliance of study  medication within the 7 day s before spirometry  assess ment 
(less than a total number of 5 doses)
80-100% Compliance of study  medication within the 7 day s before spirometry  assessment
(more or equal a total number of 5doses)
Novartis For business use only Page 12
SAP Amendm ent 1 CQVM149B2203
6.1.3.2 Graphical p resentation of results
Individual time profiles andthe results of statistical analysis will also be presented in a graphical 
representation called forest plot showing the estimated mean differences indacaterol salts 
(acetate and maleate) to placebo and estimated difference between acetate and maleate salts and 
their confidence intervals per time point for each comparison .
6.2 Secondary  objectives
6.2.1 Variables 
Forced Expiratory Volume in 1 second (FEV1), 3 seconds (FEV3), 6 seconds (FEV6), FEV1% 
predicted, Forced Vital Capacit y (FVC), FVC% predicted and Forced Expiratory  Flow 25-75% 
(FEF25 -75%) will bemeasured at screening, pre-dose, and specific time points for 
approximately  24 hours post dose (on Days 14 and 15) in each treatment period. Additional 
lung function parameters will be derived mathematically  from the listed measurements (e.g. 
FEV1/FVC, FEV1/FEV6, FEV3/FVC, FEV3/FEV6, 1- FEV3/FVC, 1- FEV6/FVC).
For each patient, the spirometric measurements must be taken at approximately  the same
corresponding time of day  in each treatment period as closel y as practic ally possible.
Pre-bronchodilator FEV1, FEV3, FEV6, FVC, and FEF25 –75 assessments will be conducted 
atscreening.
Spirometry  timepoints following the last dose of study medication in each treatment period are 
as follows:
Day 14 predose: 
- 45 min and - 15 mi n 
Day 14/15 post -dose: 5 min, 15 min, 30 min,1 h, 2 h, 3h, 4 h, 8 h, 12 h, 23 h 15 
min, 23 h 45 min
Time to peak FEV1 (maximum FEV1 post treatment) on Day 14will be derived from the 
spirometry  timepoints following the last dose of the study medication in
each treatment period .
Standardized FEV1 AUC (0-4hr) (i.e. Area Under Curve between 5 min (=time 0h)and4h post 
dose)
on Day 14 of treatment. Area under curve for FEV1 from Spirometry data and will be 
calculated b y trapezoidal rule as follows:
       =∑(       )∗(       ) 
   
 ,       =       =  
Where ‘t’is time -point and ‘c’is FEV1 at time -point t.
T0 is initial time -point, Tn is the last time point of interest.
Peak FEV1 defined as the highest bronchodilatory  effect on FEV1 during a period of 5 min to 
4h on Day  14 of treatment. FEV1 measurements to consider defining peak FEV1 are on day  14 
+5 min, +15 min, +30 min, +1h, +2 h, +3h, +4h.
PEF will be recorded twice daily  using a Peak Flow Meter 
device, once in the morning and 
once approximately  12 h later in the evening .The morning/evening and overall (average of both 
morning and evening) PEF measurements will be averaged separatel y between day s 8 to14 of 
each treatment period and each subject.
No va r t i s Fo r  bus iness  use  on ly Page  13
SAPAmendmen t  1 CQVM149B2203
T h e  n um b e r  o f  pu f f s  o f  r e s c u e  m ed i c a t ion  t ak eni s  r e c o r d e d  tw i c e  (m o r n i n g / e v e n i n g )  by
s u b j e c t s  in  th e  eD i a ry .Th e  m o r n i n g / e v e n i n g  a n d  o v e r a l l  ( b o t h  mo rn ing  and  ev en ing )  numb e r  
o f  p u f f s  o f  r e s cu e  m ed i c a t ion  w i l l  b ea v e r a g e ds e p a r a t e l y  b e tw e e n  d ay s  8  to  14  o f  e a c h  t r e a tm en t  
p e r i o d  a n d  e a c h  s u b j e c t .
B e l ow  i s  a n  e x am p l e  f o r  a v e r a g i n g  t h e  r e s c u e  m ed i c a t ion  f o r  e a c h  t r e a tm e n t  p e r i o d  a n d  s u b j e c t .
6 .2 .2 Desc r ip t ive  ana lyses
A l l  t h e  a b o v e  s e cond a ry  v a r i a b l e s  w i l l  b e  l i s t ed  b y  t r e a tm e n t  s e q u e n c e ,  sub j e c t  a n d  v i s i t / t im e
a n d  d e s c r i p t i v e  summ a ry  s t a t i s t i c s  w i l l  b e  p rov id ed  by  t r e a tm e n t  and  v i s i t / t im e .S umm a r y  
s t a t i s t i c s  w i l l  i n c l u d e  a r i t hm e t i c  m e a n ,  SD ,  CV  ( a r i t hm e t i c ) ,  m e d i a n ,  m i n im um  a n dm ax imum .
T h e  m e a n  m o r n i n g / e v e n i n g  a n d  o v e r a l l  n um b e ro f  p u f f s  o f  r e s c u e  m e d i c a t i o n  u s ew i l l  b e  l i s t ed  
by  t r e a tm e n t  s equ en c e  a n d  s u b j e c t  a n d  summ a r ys t a t i s t i c s  byt r e a tm en t .  T h e  numb e r  and  
p e r c e n t a g e  o f  sub j e c t s  w i th  r e s c u e  m ed i c a t ion s ,  t o g e t h e r  w i th  th enumb e r  o f  pu f f s,  w i l l  b e
t a b u l a t e d  b y  t r e a tm e n t .
T h e  a v e r a g e  m o r n i n g / e v e n i n g  a n d  t h e  o v e r a l l  PEF  (L /m i n )  w i l l  b e  l i s t ed  by  t r e a tm e n t  s equ en c e  
a n ds u b j e c t  a n d  s umm a r y  s t a t i s t i c sby  t r e a tm e n t .
6 .2 .3 S ta t is t ica l  mode l ,  assump t ions  and  hypo theses
A l l  t h e  a b o v e  s e cond a ry  v a r i a b l e s( S e c t i o n  6 . 2 . 1)  fo r  s p i rom e t ry  ( ex c lud ing T im e  to  p e a k  FEV 1 ,  
S t a n d a r d i z e d  FEV 1  AUC  ( 0 - 4 h r ) ,  P e a k  FEV 1 ,  A v e r a g er e s c u e  m ed i c a t ion  f o r  mo rn ing / ev en ing  
a n d  A v e r a g e  PEF  m e a s u r em e n t s  f o r  m o r n i n g / e v e n i n g)  a f t e r  1 4  d ay s  o f  t r e a tm e n t  w i l l  b e
a n a l y zed  u s ing  r e p e a t e d  m e a s u r e s  o f  ANOVA  i n c l u d i n g  t r e a tm e n t ,  p e r iod ,s e q u e n c e ,  t im e ,  
t r e a tm e n t  by  t im ea s  f ix ed  e f f e c t s  and  s u b j e c t  n e s t ed  w i th in  s equ en c e  w i l l  b e  in c lud ed  a s  a  
r a n d om  e f f e c t .  T im e  w i l l  b e  r e p e a t e d  w i th in  e a c h  s u b j e c t * p e r i o di n t e r a c t i o n  t e rm .An  
u n s t r u c t u r e d  v a r i a n c e  u n s t r u c t u r e d  c o v a r i a n c e  m a t r i xw i l l  b e  a p p l i e d .
S t a n d a r d i z e d  FEV 1  AUC( 0 - 4 h r )b e tw e e nb a s e l in e( p r e  d o s e )  a n d  4 h  p o s t  d o s e  a n d  p e a k  FEV 1  
o n  D ay 1 4  o f  t r e a tm e n t  w i l l  b e  an a ly z ed  u s i n g  th e  s am em o d e l  (ANOVA )  a s  f o r  t h e  p r im a r y  
a n a l y si s .
A v e r a g e d  m o r n i n g / e v e n i n g  a n d  ov e r a l l  n um b e r  o f  p u f f s  o f  r e s c u e  m e d i c a t i o na n d  a v e r a g e  
m o r n i n g / e v e n i n g  a n d  ov e r a l l  n um b e r  o f  PEF  m e a s u r em e n t s  w i l l  b e  an a l y z e d  u s i n g  t h e  s am e  
mod e l  (ANOVA )  a s  fo r  p r im a ry a n a l y si s .
T im e  to  p e a k  FEV 1  o n  D ay 1 4  w i l l  b e  an a ly z ed  u s i n g  n o n - p a r am e t r i c  m e t h o d s .  T h e  m e d i a n
d i f f e r e n c e  and  th e  tw o - s id ed95%  con f id en c e  in t e rv a l  o f  th e  m ed i an  d i f f e r en c e  in  t im e  to  p e ak
FEV 1  w i l l  b e  e s t im a t e d  u s i n g  H o d g e s- L e hm a n n  e s t im a t i o n  p r o c e d u r e .Co rpo ra te  Con f iden t ia l  In fo rma t ion
Novartis For business use only Page 14
SAP Amendm ent 1 CQVM149B2203
6.2.3.1 Model checking procedures
For the FEV1 AUC (0-4h r)if anobserv ation is missing between two non- missing observations, 
the AUC will be linearly interpolated between the two 
non-missing values i.e. the subject ‘s 
profile will be assumed to be linear between the two available values. Multiple occurrences of 
such missing values (an observation missing between adjacent non-missing observations) will 
be handled in a similar manner. But in case of missing consecutive assessments, then the patient 
profile will be excluded from anal ysis.No imputation will be made if either the first or the last 
observation is missing and AUC (0-4hr) is calculated from the available part of the profile 
ignoring the first and last time points
. 
For all secondary  end points, i f apatient takes rescue medicat ion within 6hprior to the 
spirometry  assessments and the visit is not rescheduled to the next day then all spirometry 
assessments data from this visit and the following visits in this treatment period will be set to 
missing. If rescue medication is taken during the 24 hour spirometry assessments then from the 
time of the rescue medication intake, all post-time point  spirometry  assessments will be 
considered as missing in this treatment period and AUC (0- 4hr) will be considered as missing .
6.2.3.2 Graphical p resentation of results
Individual time profiles and Mean (SD) plots for all secondary  parameters will be presented b y 
treatment group and time.
The results of statistical analy sis will also be presented in a graphical representation called forest 
plot showing the estimated mean differences indacaterol salts (acetate and maleate) to placebo 
and estimated difference between acetate and maleate salts and their confidence intervals per 
time point for each comparison including studentized residual plots.
6.3 Exploratory  objectives
6.3.1 Variables 
Not Applicable
6.3.2 Descriptive analy ses
Not Applicable
7 Statistical methods for safety  and tolerability  data
7.1 Variables
Adverse events, vital signs (blood pressure, pulse rate , body  temperature ), ECG intervals, 
laboratory  measurements, as well as subject demographics, baseline characteristics, and 
treatment information.
Novartis For business use only Page 15
SAP Amendm ent 1 CQVM149B2203
7.2 Descriptive analy ses
Subject demographics and other baseline characteristics
All data for background and demographic variables will be listed by treatment sequence and 
subject. Summary  statistics will be provide d for all subjects, as well as for each treatment 
sequence.
Relevant medical history, current medical conditions, results of laboratory screens, drug tests 
and an y other relevant information will be listed by treatment sequence and subject.
Subject disposi tion
A disposition summary  will be presented for all subjects. This table will present the number and 
percentage of subjects who completed each stud y epoch and discontinued early for each epoch, 
along with the reasons for earl y discontinuation. 
The number and percentage of subjects in each analysis set will be summarized for all subjects. 
All analysis set results will be presented in listings by treatment sequence and subject. A 
separate listing of all subjects excluded from any analysis set and the reason s for their exclusion 
will be provided. 
All study  epoch completion data will be listed by  treatment sequence and subject .
Treatment
Data for study  drug administration (rescue medication) and concomitant therapies will be listed 
by treatment sequence and subject.
Vital signs
All vital signs data will be listed by treatment sequence, subject, and visit/time and if ranges are 
available abnormalities (and relevant orthostatic changes) will be flagged. Summary statistics 
will be provided by  treatment and visit/ time.
ECG evaluations
All ECG data will be listed by treatment sequence, subject and visit/time, abnormalities will be 
flagged. Summary  statistics will be provided by treatment and visit/time. Summary  table for 
percentage and number of subjects with abnorm al values <40 /40-90 />90 bpm in heart rate and 
summary  table for percentage and number of subjects with notable values increase >30 / 
increase >60 / >450 />480/>500 msec in QTcF interval will be provided.
Clinical laboratory  evaluations
All laboratory  data will be listed by treatment sequence , subject, and visit/time and if normal 
ranges are available abnormalities will be flagged. A separate listing is provided presenting all 
parameters in a subject with any abnormal values. Summary  statistics will be provided by 
treatment and visit/time.
Summary  table for percentage and number of subjects with notable values for serum potassium 
(<3 /3- <3.5 />5.5 mmol/L) and plasma glucose (>10 -15 />15 mmol/L ) will be provided.
Novartis For business use only Page 16
SAP Amendm ent 1 CQVM149B2203
Adverse events
All information obtained on adverse events will be display ed by treatment and subject.
All treatment emergent adverse events will be summarized. Adverse events starting on or after 
thetime of the first inhalation of study  drug will be classified as a treatment emergent adverse
even t. Any adverse events that started during a washout period will be assigned to the treatment 
period just prior to that washout period. An y adverse events that started during the study  before 
the time of the first inhalation of study  drug of the first perio d will be classified as a prior 
adverse event and will not be summarized .
The number and percentage of subjects with treatment emergent adverse event will be 
summarized by  treatment , overall by  system organ class and preferred term, overall by  system 
organ class, preferred term and maximum severity, suspected drug-related adverse events by 
system organ class and preferred term, serious adverse events by system organ class and 
preferred term, andadverse events leading to permanent discontinuation of study  drug by 
system organ class and preferred term with a breakdown by  treatment. A subject with multiple 
adverse events within a body  system and treatment period is only counted once towards the 
total of this body  system and treatment.
For the legal requiremen ts of ClinicalTrials.gov and EudraCT, two required tables on treatment 
emergent adverse events which are not serious adverse events with an incidence greater than 
5% and on treatment emergent serious adverse events and SAE suspected to be related to stud y 
treatment will be provided by system organ class and preferred term on the safet y analysis set 
population.
If for a same patient, several consecutive AEs (irrespective of study  treatment causalit y, 
seriousness and severit y) occurred with the same SOC and P T:
a single occurrence will be counted if there is ≤ 1 day  gap between the end date of the 
preceding AE and the start date of the consecutive AE
more than one occurrence will be counted if there is > 1 day  gap between the end date 
of the preceding AE and the start date of the consecutive AE .
For occurrence, the presence of at least one SAE / SAE suspected to be related to study 
treatment / non SAE has to be checked in a block e.g., among AE's in a ≤ 1 day  gap block, if at 
least one SAE is occurring, then one occurrence is calculated for that SAE.
The number of deaths resulting from SAEs suspected to be related to study  treatment and SAEs 
irrespective of study  treatment relationship will be provided by  SOC and PT. 
Protocol Deviations
Protocol deviations wi
ll be listed by  treatment sequence and subject.
Liver events
Liver event data ma y be reported in listings and summaries if data is collected during the study.
No va r t i s Fo r  bus iness  use  on ly Page  17
SAPAmendmen t  1 CQVM149B2203
7 .3 G raph ica l  p resen ta t ion  
Co rpo ra te  Con f iden t ia l  In fo rma t ionBoxp lo t s  to  v i su a l i z e  t r e n d s  in  long i tud in a l  s a f e t y  d a t a  ( v i t a l s ,  ECG,  l a b  p a r am e t e r )  w i l l  b e  
c r e a t e d .